Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors

Asako Machidori, Masaki Shiota, Satoshi Kobayashi, Takashi Matsumoto, Keisuke Monji, Eiji Kashiwagi, Ario Takeuchi, Ryosuke Takahashi, Junichi Inokuchi, Masatoshi Eto

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Background: This study investigated the prognostic significance of complete blood count data in castration-resistant prostate cancer patients treated using androgen receptor pathway inhibitors (ARPIs). Patients and Methods: Patients treated with an ARPI, abiraterone or enzalutamide, as first-line therapy for castration-resistant prostate cancer from 2014 to 2018 were included. The association between complete blood count data and prognoses including progression-free survival and overall survival (OS) was investigated. Results: High white blood cell counts (<median vs. ≥median; hazard ratio [HR], 1.82, 95% confidence interval [CI], 1.14–2.89; P = 0.012) and high neutrophil-to-lymphocyte ratios (<median vs. ≥median; HR, 1.90, 95% CI, 1.11–3.27; P = 0.020) were associated with a high risk of progression in univariate analysis. In univariate analysis, high hemoglobin (Hb) levels (<median vs. ≥median; HR, 0.41, 95% CI, 0.24–0.73; P = 0.0023) and high red cell distribution widths (<median vs. ≥median; HR, 2.41, 95% CI, 1.37–4.25; P = 0.0023) were associated with a low and a high risk of all-cause mortality, respectively. In multivariate analysis, high Hb levels (<median vs. ≥median; HR, 0.42, 95% CI, 0.22–0.79; P = 0.0076) were repeatedly associated with a low risk of all-cause mortality. Conclusion: We found that white blood cell counts and neutrophil-to-lymphocyte ratios may be prognostic for progression-free survival while red cell distribution widths may be prognostic for OS. In particular, a low Hb level was a robust prognostic factor for poor OS. These findings could be useful in predicting prognosis in CRPC patients treated with ARPIs.

Original languageEnglish
Pages (from-to)365.e1-365.e7
JournalUrologic Oncology: Seminars and Original Investigations
Volume39
Issue number6
DOIs
Publication statusPublished - Jun 2021

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Fingerprint

Dive into the research topics of 'Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors'. Together they form a unique fingerprint.

Cite this